Clinical and laboratory evaluation of sicca complaints: distinctive aspects of primary, secondary and non-Sjogren syndrome

Table 3 Statistical correlations among the clinical and laboratory findings from patients in primary Sjögren’s Syndrome (pSS) group

Variables	N	Spearman r*	95% CI	p value
Age vs. SSa	198	− 0.26	− 0.46 to − 0.04	0.024
Age vs. SSb	184	− 0.20	− 0.34 to − 0.05	0.006
Age vs. CFS	170	0.26	0.02 to 0.47	0.029
CFS vs. TBUT	105	− 0.38	− 0.54 to − 0.20	< 0.0001
SSb vs. C3	171	− 0.24	− 0.43 to − 0.04	0.014
SSb vs. C4	171	− 0.25	− 0.39 to − 0.10	0.0009
B2M vs. C3	169	− 0.24	− 0.38 to − 0.09	0.0013
B2M vs. LDH	122	0.21	0.03 to 0.37	0.020
B2M vs. ESSDAI	120	0.20	0.02 to 0.37	0.025
B2M vs. CFS	109	0.27	0.08 to 0.44	0.003
Cryo vs. C4	105	− 0.21	− 0.39 to − 0.01	0.026

^*Spearman test, two-tailed; SSa anti-Ro (IU/ml); SSb anti-La (IU/ml); CFS corneal fluorescein staining score; TFBUT tear film break up time (seconds); C3 levels of complement component 3 measured in the blood (g/l); C4 levels of complement component 4 measured in the blood (g/l); B2M beta 2 microglobulin (ng/ml); LDH lactate dehydrogenase (IU/L); ESSDAI EULAR SS disease activity index; Cryo cryoglobulins

ISSN: 2523-3106